 2. Subjects who have received any anticancer therapy within 21 days prior to study entry for cytotoxic agents 42 days for mitomycin C and nitrosoureas, radiotherapy, hormonal, biological including humanized antibodies and targeted agents, or within 30 days for an investigational agent. 